Cell therapy added after brain surgery and chemo-radiation
Part of Brain & nervous system, Cancer clinical trials.
This Phase 3 trial tests whether adding a patient-specific immune cell treatment (made from your blood) after surgery and standard radiation plus temozolomide (RT/TMZ) can help people with newly diagnosed glioblastoma (GBM). It’s designed to see if the added therapy improves outcomes compared with standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 and have a new (presumptive) diagnosis of primary glioblastoma, with a plan for surgery to remove tumor tissue
- You agree to provide tumor tissue and blood for immune-cell making (leukapheresis) and sign consent
- Your GBM diagnosis is confirmed by pathology after surgery
- You plan to start standard radiation plus temozolomide (RT/TMZ) soon after surgery
- You either have high or moderate functional status (KPS 90–100 or 70–80), and you meet the study’s other tumor biology targets (MGMT and IDH results)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a personalized vaccine (made from your own immune cells and tumor 'neoantigens') combined with the chemotherapy drug temozolomide for people with newly diagnosed glioblastoma. The goal is to see if adding the vaccine helps the immune system better fight the tumor.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This Phase 2 study tests ADCV01, given “on top of” other standard treatment, for newly diagnosed glioblastoma (grade 4 brain tumor). The goal is to see whether it helps patients live longer and safely manage tumor growth.
This trial tests giving a patient’s own stem cells back to help the bone marrow recover after treatment for newly diagnosed glioblastoma or gliosarcoma. It may help reduce blood-count problems so treatment can be given more safely.
Hear when a new Primary Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.